arrow Log In to View Account     |          

Thursday, March 29th at 9:00 PM ET

Presenters: Susan Goodin, PharmD
and Laura B. Michaud, PharmD, BCOP, FASHP, CMQ

This webcast will provide live credit (L) for those states requiring it.

The management of patients with advanced or metastatic hormone-receptor positive breast cancer (HR-BC) continues to challenge clinicians particularly as a significant number of patients develop resistance to hormonal therapies. The use of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors, a novel class of targeted small molecules, offers an opportunity to revolutionize treatment paradigms by mitigating the development of resistance and by offering alternative options for patients who are resistant. In 2015, the US Food and Drug Administration (FDA) approved the first-in-class CDK 4/6 inhibitor as a novel treatment for patients with HR-BC. A second agent received FDA approval in March 2017, and the role of CDK 4/6 inhibitors was recently incorporated into practice guidelines. Through case-based presentations and expert discussion, this live webcast will present the most up-to-date information on the use of CDK 4/6 inhibitors in patients with HR-BC, including mechanism of action, clinical trial data, adverse event management, and pharmacist-driven strategies to improve outcomes.

The goal of this activity is to provide pharmacists with the most up-to-date information on the use of CDK 4/6 inhibitors in HR-BC.

This activity has been designed to meet the needs of oncology, health system, managed care, specialty pharmacists and other pharmacists who manage patients receiving systemic therapy for HR-positive breast cancer. No prerequisites required.

  • Introduction
  • New Therapy for Advanced/Metastatic HR-BC:
    CDK 4/6 Inhibition
  • Evaluation of Data:
    Comparisons of Clinical Trial and Real-World Data
  • Case Presentations:
    Application to Pharmacy Practice
  • Conclusions and Q & A
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
  • DESCRIBE the MOA of CDK 4/6 inhibition and rationale for use in the treatment of HR-BC.
  • EVALUATE clinical trial data for CDK 4/6 inhibitors in the treatment of HR-BC.
  • APPLY real-world CDK 4/6 data to patient-specific scenarios related to drug dosing, AE monitoring and patient selection.
Susan Goodin, PharmD
Executive Director, Statewide Affairs
Rutgers Cancer Institute of New Jersey
Professor of Medicine
Robert Wood Johnson Medical School
New Brunswick, New Jersey

Laura B. Michaud, PharmD, BCOP, FASHP, CMQ
Clinical Pharmacy Manager
University of Texas MD Anderson Cancer Center
Houston, Texas

acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.5 live contact hours of credit (0.15 CEUs). Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the activity; 3) completing the self-assessment instrument with a score of at least 70%. A statement of CE credit will available for download following successful completion of the educational activity. UAN: 0064-0000-17-213-LO1-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted..

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website:
To receive credit for your participation in this activity, all pharmacists must include their CORRECT NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.

A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

There is no fee for this educational activity.

<img src="" alt="procced to pretest" border="0" />
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.